Down-Regulation of Protein Kinase Cδ Inhibits Inducible Nitric Oxide Synthase Expression through IRF1

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Leppänen, Tiina ^a   Korhonen, Riku ^a   Laavola, Mirka ^a   Nieminen, Riina ^a   Tuominen, Raimo K ^b   Moilanen, Eeva ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA; L NIL; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN KINASE C DELTA; ROTTLERIN; SMALL INTERFERING RNA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PAW EDEMA; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ACETOPHENONES; ANIMALS; BENZOPYRANS; BLOTTING, WESTERN; CARRAGEENAN; CELL LINE; DOWN-REGULATION; EDEMA; ENZYME INHIBITORS; FIBROBLASTS; HINDLIMB; INTERFERON REGULATORY FACTOR-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYSINE; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN KINASE C-DELTA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA STABILITY; STAT1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS); MUS;

EID: 84872256730     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052741     Document Type: Article

References (57)

1. Korhonen R, Lahti A, Kankaanranta H, Moilanen E, (2005) Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 4: 471-479.
2. Tripathi P, Tripathi P, Kashyap L, Singh V, (2007) The role of nitric oxide in inflammatory reactions. FEMS Immunol Med Microbiol 51: 443-452.
3. Vuolteenaho K, Moilanen T, Knowles RG, Moilanen E, (2007) The role of nitric oxide in osteoarthritis. Scand J Rheumatol 36: 247-258.
4. Yamagishi S, Matsui T, (2011) Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe? Pharmacol Res 64: 187-194.
5. Alderton WK, Cooper CE, Knowles RG, (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615.
6. Pautz A, Art J, Hahn S, Nowag S, Voss C, et al. (2010) Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 23: 75-93.
7. Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, et al. (1994) Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263: 1612-1615.
8. Xie QW, Kashiwabara Y, Nathan C, (1994) Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 269: 4705-4708.
9. Fujimura M, Tominaga T, Kato I, Takasawa S, Kawase M, et al. (1997) Attenuation of nitric oxide synthase induction in IRF-1-deficient glial cells. Brain Res 759: 247-250.
10. Ohmori Y, Hamilton TA, (2001) Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol 69: 598-604.
11. Gao J, Morrison DC, Parmely TJ, Russell SW, Murphy WJ, (1997) An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J Biol Chem 272: 1226-1230.
12. Tinker AC, Wallace AV, (2006) Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases? Curr Top Med Chem 6: 77-92.
13. Hofmann J, (2004) Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 4: 125-146.
14. Spitaler M, Cantrell DA, (2004) Protein kinase C and beyond. Nat Immunol 5: 785-790.
15. Steinberg SF, (2004) Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J 384: 449-459.
16. Lee MR, Duan W, Tan SL, (2008) Protein kinase C isozymes as potential therapeutic targets in immune disorders. Expert Opin Ther Targets 12: 535-552.
17. Leitges M, Mayr M, Braun U, Mayr U, Li C, et al. (2001) Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. J Clin Invest 108: 1505-1512.
18. Miyamoto A, Nakayama K, Imaki H, Hirose S, Jiang Y, et al. (2002) Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature 416: 865-869.
19. Mecklenbräuker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A, (2002) Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature 416: 860-865.
20. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, et al. (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126: 131-138.
21. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
22. Leppänen T, Jalonen U, Korhonen R, Tuominen RK, Moilanen E, (2010) Inhibition of protein kinase Cdelta reduces tristetraprolin expression by destabilizing its mRNA in activated macrophages. Eur J Pharmacol 628: 220-225.
23. Salonen T, Sareila O, Jalonen U, Kankaanranta H, Tuominen R, et al. (2006) Inhibition of classical PKC isoenzymes downregulates STAT1 activation and iNOS expression in LPS-treated murine J774 macrophages. Br J Pharmacol 147: 790-799.
24. Felley-Bosco E, Bender FC, Courjault-Gautier F, Bron C, Quest AF, (2000) Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc Natl Acad Sci U S A 97: 14334-14339.
25. Musial A, Eissa NT, (2001) Inducible nitric-oxide synthase is regulated by the proteasome degradation pathway. J Biol Chem 276: 24268-24273.
26. Paukkeri EL, Leppänen T, Sareila O, Vuolteenaho K, Kankaanranta H, et al. (2007) PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. Br J Pharmacol 152: 1081-1091.
27. Korhonen R, Lahti A, Hämäläinen M, Kankaanranta H, Moilanen E, (2002) Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide production by destabilizing mRNA in lipopolysaccharide-treated macrophages. Mol Pharmacol 62: 698-704.
28. Kleinert H, Schwarz PM, Förstermann U, (2003) Regulation of the expression of inducible nitric oxide synthase. Biol Chem 384: 1343-1364.
29. Lahti A, Jalonen U, Kankaanranta H, Moilanen E, (2003) c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages. Mol Pharmacol 64: 308-315.
30. Korhonen R, Linker K, Pautz A, Förstermann U, Moilanen E, et al. (2007) Post-transcriptional regulation of human inducible nitric-oxide synthase expression by the Jun N-terminal kinase. Mol Pharmacol 71: 1427-1434.
31. Gao JJ, Filla MB, Fultz MJ, Vogel SN, Russell SW, et al. (1998) Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene. J Immunol 161: 4803-4810.
32. Faggioli L, Merola M, Hiscott J, Furia A, Monese R, et al. (1997) Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon-gamma. Eur J Immunol 27: 3022-3030.
33. Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, et al. (1996) Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 118: 829-838.
34. Handy RL, Moore PK, (1998) A comparison of the effects of L-NAME, 7-NI and L-NIL on carrageenan-induced hindpaw oedema and NOS activity. Br J Pharmacol 123: 1119-1126.
35. Gschwendt M, Müller HJ, Kielbassa K, Zang R, Kittstein W, et al. (1994) Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199: 93-98.
36. Davies SP, Reddy H, Caivano M, Cohen P, (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
37. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
38. Shaw G, Kamen R, (1986) A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46: 659-667.
39. Lowenstein CJ, Glatt CS, Bredt DS, Snyder SH, (1992) Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc Natl Acad Sci U S A 89: 6711-6715.
40. Lyons CR, Orloff GJ, Cunningham JM, (1992) Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem 267: 6370-6374.
41. Korhonen R, Linker K, Pautz A, Förstermann U, Moilanen E, et al. (2007) Post-transcriptional regulation of human inducible nitric-oxide synthase expression by the Jun N-terminal kinase. Mol Pharmacol 71: 1427-1434.
42. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, et al. (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268: 726-731.
43. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, et al. (1993) Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci U S A 90: 9730-9734.
44. Bhatt KH, Pandey RK, Dahiya Y, Sodhi A, (2010) Protein kinase Cdelta and protein tyrosine kinase regulate peptidoglycan-induced nuclear factor-kappaB activation and inducible nitric oxide synthase expression in mouse peritoneal macrophages in vitro. Mol Immunol 47: 861-870.
45. Shiraishi A, Dudler J, Lotz M, (1997) The role of IFN regulatory factor-1 in synovitis and nitric oxide production. J Immunol 159: 3549-3554.
46. Blair LA, Maggi LB Jr, Scarim AL, Corbett JA, (2002) Role of interferon regulatory factor-1 in double-stranded RNA-induced iNOS expression by mouse islets. J Biol Chem 277: 359-365.
47. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D, (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol 162: 4685-4696.
48. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, et al. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442.
49. Durbin JE, Hackenmiller R, Simon MC, Levy DE, (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
50. Sato M, Taniguchi T, Tanaka N, (2001) The interferon system and interferon regulatory factor transcription factors - studies from gene knockout mice. Cytokine Growth Factor Rev 12: 133-142.
51. Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, et al. (2002) IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 22: 39-47.
52. Dugo L, Marzocco S, Mazzon E, Di Paola R, Genovese T, et al. (2004) Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation. Br J Pharmacol 141: 979-987.
53. Harkin DW, Rubin BB, Romaschin A, Lindsay TF, (2004) Selective inducible nitric oxide synthase (iNOS) inhibition attenuates remote acute lung injury in a model of ruptured abdominal aortic aneurysm. J Surg Res 120: 230-241.
54. Peng X, Abdulnour RE, Sammani S, Ma SF, Han EJ, et al. (2005) Inducible nitric oxide synthase contributes to ventilator-induced lung injury. Am J Respir Crit Care Med 172: 470-479.
55. Sittipunt C, Steinberg KP, Ruzinski JT, Myles C, Zhu S, et al. (2001) Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 163: 503-510.
56. Kilpatrick LE, Standage SW, Li H, Raj NR, Korchak HM, et al. (2011) Protection against sepsis-induced lung injury by selective inhibition of protein kinase C-delta (delta-PKC). J Leukoc Biol 89: 3-10.
57. Taki S, Sato T, Ogasawara K, Fukuda T, Sato M, et al. (1997) Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6: 673-679.